These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29255745)

  • 1. Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.
    Andrade P; Rodrigues S; Rodrigues-Pinto E; Gaspar R; Lopes J; Lopes S; Macedo G
    GE Port J Gastroenterol; 2017 Jul; 24(4):161-168. PubMed ID: 29255745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.
    Rout G; Kedia S; Nayak B; Yadav R; Das P; Acharya SK; Gunjan D; Singh V; Mahanta M; Gupta S; Aggarwal S; Shalimar
    J Clin Exp Hepatol; 2019; 9(1):13-21. PubMed ID: 30765934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
    Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
    World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.
    Lupșor-Platon M; Feier D; Stefănescu H; Tamas A; Botan E; Sparchez Z; Maniu A; Badea R
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):35-42. PubMed ID: 25822432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.
    Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Dal Bello B; Filice G; Filice C
    World J Gastroenterol; 2014 Jun; 20(21):6626-31. PubMed ID: 24914387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
    Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.
    Baumeler S; Jochum W; Neuweiler J; Bergamin I; Semela D
    Swiss Med Wkly; 2019 Apr; 149():w20077. PubMed ID: 31026041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
    EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
    Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.
    Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A
    Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
    Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
    Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound and FibroScan
    Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
    Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Accuracy and Optimal Cut-off of Controlled Attenuation Parameter for the Detection of Hepatic Steatosis in Indian Population.
    Kuchay MS; Choudhary NS; Sharma D; Krishan S; Mishra SK; Wasir JS; Singh MK; Saraf N; Dhampalwar S; Sud R
    J Clin Exp Hepatol; 2022; 12(3):893-898. PubMed ID: 35677514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
    Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
    J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
    J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.
    Yilmaz Y; Yesil A; Gerin F; Ergelen R; Akin H; Celikel ÇA; Imeryuz N
    Scand J Gastroenterol; 2014 May; 49(5):611-6. PubMed ID: 24611771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.